Literature DB >> 10737370

Salvage surgery for recurrent primary nasopharyngeal carcinoma.

W I Wei1.   

Abstract

Recurrent primary nasopharyngeal carcinoma after radiotherapy exhibits wide local extension [Uttley D, Moore A, Archer DJ. J Neurosurg 1989;71:705-10]. This wide exposure of the nasopharynx and its vicinity is essential for an oncological radical resection to be carried out. The resection should embrace the tumor with an adequate mucosal margin including the cartilaginous portion of the Eustachian tube. Paranasopharyngeal tissues should be included in the resection whenever indicated. The anterolateral approach to the nasopharynx and the paranasopharyngeal space provides adequate exposure required for an oncological resection. Morbidity associated with the operation is low and this is recommended for resection of most recurrent primary nasopharyngeal carcinoma after radiotherapy.

Entities:  

Mesh:

Year:  2000        PMID: 10737370     DOI: 10.1016/s1040-8428(99)00069-4

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  13 in total

1.  Combined transoral transnasal robotic-assisted nasopharyngectomy: a cadaveric feasibility study.

Authors:  Iacopo Dallan; Paolo Castelnuovo; Filippo Montevecchi; Paolo Battaglia; Niccolò Cerchiai; Veronica Seccia; Claudio Vicini
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-03-18       Impact factor: 2.503

Review 2.  Current treatment options for recurrent nasopharyngeal cancer.

Authors:  Carlos Suárez; Juan P Rodrigo; Alessandra Rinaldo; Johannes A Langendijk; Ashok R Shaha; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-09-24       Impact factor: 2.503

3.  Prognostic model for survival of local recurrent nasopharyngeal carcinoma with intensity-modulated radiotherapy.

Authors:  Y-M Tian; Y-H Tian; L Zeng; S Liu; Y Guan; T-X Lu; F Han
Journal:  Br J Cancer       Date:  2013-12-12       Impact factor: 7.640

4.  Diagnosis of post-radiotherapy local failures in nasopharyngeal carcinoma: a prospective institutional study.

Authors:  Puneet Kumar Bagri; Mukesh Kumar Singhal; Daleep Singh; Akhil Kapoor; Shankar Lal Jakhar; Neeti Sharma; Surender Beniwal; Harvindra Singh Kumar; Ajay Sharma; Megh Raj Bardia
Journal:  Iran J Cancer Prev       Date:  2014

5.  Neoadjuvant and Concurrent Chemotherapy Have Varied Impacts on the Prognosis of Patients with the Ascending and Descending Types of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy.

Authors:  Ji-Jin Yao; Guan-Qun Zhou; Fan Zhang; Wang-Jian Zhang; Li Lin; Ling-Long Tang; Yan-Ping Mao; Jun Ma; Ying Sun
Journal:  PLoS One       Date:  2016-10-26       Impact factor: 3.240

6.  Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.

Authors:  T Finazzi; T Rordorf; K Ikenberg; G F Huber; M Guckenberger; H I Garcia Schueler
Journal:  BMC Cancer       Date:  2018-04-06       Impact factor: 4.430

7.  The challenge in treating locally recurrent T3-4 nasopharyngeal carcinoma: the survival benefit and severe late toxicities of re-irradiation with intensity-modulated radiotherapy.

Authors:  Yun-Ming Tian; Wei-Zeng Huang; Xia Yuan; Li Bai; Chong Zhao; Fei Han
Journal:  Oncotarget       Date:  2017-06-27

8.  Benefits of local tumor excision and pharyngectomy on the survival of nasopharyngeal carcinoma patients: a retrospective observational study based on SEER database.

Authors:  Jian Sun; Zhongying Huang; Zheyu Hu; Rui Sun
Journal:  J Transl Med       Date:  2017-05-30       Impact factor: 5.531

9.  Comparison of single versus fractionated dose of stereotactic radiotherapy for salvaging local failures of nasopharyngeal carcinoma: a matched-cohort analysis.

Authors:  Daniel T T Chua; Shao-Xiong Wu; Victor Lee; Janice Tsang
Journal:  Head Neck Oncol       Date:  2009-05-23

10.  Validation of a prognostic scoring system for locally recurrent nasopharyngeal carcinoma treated by stereotactic radiosurgery.

Authors:  Daniel T T Chua; Kwan-Ngai Hung; Victor Lee; Sherry C Y Ng; Janice Tsang
Journal:  BMC Cancer       Date:  2009-04-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.